FASN inhibition as a potential treatment for endocrine-resistant breast cancer
نویسندگان
چکیده
منابع مشابه
S100β as a serum marker in endocrine resistant breast cancer
BACKGROUND Endocrine therapy is standard treatment for estrogen receptor (ER)-positive breast cancer. However, its efficacy is limited by intrinsic and acquired resistance. Here the potential of S100β as a biomarker and inhibition of its signaling network as a therapeutic strategy in endocrine treated patients was investigated. METHODS The expression of S100β in tissue and serum was assessed ...
متن کامل172ptriple Negative Breast Cancer: Clinicopathologic Characteristics and Fatty Acid Synthase (fasn) Expression as a Potential Target.
Aim: Triple negative breast cancer (TNBC) is defined by the lack of estrogen and progesterone receptors expression and the absence of human epidermal growth factor receptor 2 amplification. TNBC has specific clinical/pathological features and molecular biology. The absence of effective targeted therapies requires new biomarkers to develop therapeutic strategies. FASN, the sole mammalian enzyme ...
متن کاملImmunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملNeoadjuvant Endocrine Treatment for Breast Cancer
25/18_suppl/538; cited December 9, 2013] 35. Ali AM, Provenzano E, Bartlett JM. et al. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the neat/br9601 trial. Int J Cancer 2013;133:1470–8. 36. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor–positive breast cancer based on postneoadjuvan...
متن کاملReactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.
Endocrine therapy has been highly effective for the treatment of estrogen receptor-positive breast cancer, but endocrine resistance develops in a significant proportion of patients. In an effort to develop novel therapeutic strategies for the treatment of endocrine-resistant breast cancer, we have evaluated a potent and specific MDM2-p53 interaction inhibitor, MI-77301, which has been advanced ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer Research and Treatment
سال: 2021
ISSN: 0167-6806,1573-7217
DOI: 10.1007/s10549-021-06231-6